TransMedics Group Inc. (TMDX)
TransMedics Statistics
Share Statistics
TransMedics has 33.66M shares outstanding. The number of shares has increased by 2.2% in one year.
Shares Outstanding | 33.66M |
Shares Change (YoY) | 2.2% |
Shares Change (QoQ) | 0.3% |
Owned by Institutions (%) | 99.99% |
Shares Floating | 32.43M |
Failed to Deliver (FTD) Shares | 51 |
FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 8.99M, so 26.79% of the outstanding shares have been sold short.
Short Interest | 8.99M |
Short % of Shares Out | 26.79% |
Short % of Float | 27.73% |
Short Ratio (days to cover) | 3.54 |
Valuation Ratios
The PE ratio is 58.42 and the forward PE ratio is 45.96. TransMedics's PEG ratio is -0.24.
PE Ratio | 58.42 |
Forward PE | 45.96 |
PS Ratio | 4.69 |
Forward PS | 2.2 |
PB Ratio | 9.06 |
P/FCF Ratio | 42.45 |
PEG Ratio | -0.24 |
Enterprise Valuation
TransMedics has an Enterprise Value (EV) of 2.19B.
EV / Sales | 4.97 |
EV / EBITDA | 31.37 |
EV / EBIT | 44.96 |
EV / FCF | 44.96 |
Financial Position
The company has a current ratio of 8.3, with a Debt / Equity ratio of 2.01.
Current Ratio | 8.3 |
Quick Ratio | 7.52 |
Debt / Equity | 2.01 |
Debt / EBITDA | 6.56 |
Debt / FCF | 9.4 |
Interest Coverage | 2.6 |
Financial Efficiency
Return on Equity is 15.51% and Return on Invested Capital is 4.98%.
Return on Equity | 15.51% |
Return on Assets | 4.41% |
Return on Invested Capital | 4.98% |
Revenue Per Employee | $606.51K |
Profits Per Employee | $48.71K |
Employee Count | 728 |
Asset Turnover | 0.55 |
Inventory Turnover | 3.85 |
Taxes
Income Tax | 316K |
Effective Tax Rate | 0.88% |
Stock Price Statistics
The stock price has increased by -2.79% in the last 52 weeks. The beta is 2.12, so TransMedics's price volatility has been higher than the market average.
Beta | 2.12 |
52-Week Price Change | -2.79% |
50-Day Moving Average | 69.56 |
200-Day Moving Average | 107.65 |
Relative Strength Index (RSI) | 57.27 |
Average Volume (20 Days) | 1.68M |
Income Statement
In the last 12 months, TransMedics had revenue of 441.54M and earned 35.46M in profits. Earnings per share was 1.07.
Revenue | 441.54M |
Gross Profit | 262.08M |
Operating Income | 37.5M |
Net Income | 35.46M |
EBITDA | 69.95M |
EBIT | 50.19M |
Earnings Per Share (EPS) | 1.07 |
Balance Sheet
The company has 336.65M in cash and 458.92M in debt, giving a net cash position of -122.27M.
Cash & Cash Equivalents | 336.65M |
Total Debt | 458.92M |
Net Cash | -122.27M |
Retained Earnings | -468.24M |
Total Assets | 804.08M |
Working Capital | 437.3M |
Cash Flow
In the last 12 months, operating cash flow was 48.8M and capital expenditures 0, giving a free cash flow of 48.8M.
Operating Cash Flow | 48.8M |
Capital Expenditures | 0 |
Free Cash Flow | 48.8M |
FCF Per Share | 1.47 |
Margins
Gross margin is 59.36%, with operating and profit margins of 8.49% and 8.03%.
Gross Margin | 59.36% |
Operating Margin | 8.49% |
Pretax Margin | 8.1% |
Profit Margin | 8.03% |
EBITDA Margin | 15.84% |
EBIT Margin | 8.49% |
FCF Margin | 11.05% |
Dividends & Yields
TMDX does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | 1.71% |
FCF Yield | 2.36% |
Analyst Forecast
The average price target for TMDX is $112, which is 52.9% higher than the current price. The consensus rating is "Buy".
Price Target | $112 |
Price Target Difference | 52.9% |
Analyst Consensus | Buy |
Analyst Count | 11 |
Scores
Altman Z-Score | 3.77 |
Piotroski F-Score | 7 |